-
6 days ago | 
dermatologytimes.com | Kaitlyn Bader
Corvus Pharmaceuticals recently announced new interim data for its randomized, double-blind, placebo-controlled phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis (AD) who have failed one prior topical or systemic therapy.
-
2 weeks ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“I introduce the idea of topical non-steroidals very early. I think that when you really try to emphasize the fact that topical steroids were made for certain things and not made for others, it makes that discussion a little easier when you try to introduce some of our newer options,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
2 weeks ago | 
dermatologytimes.com | Kaitlyn Bader
“Steroid phobia is at an all-time high, but if it had to happen at any time in history, I'm so glad it's now because we're prepared. We have other options that we can use to help manage our patients with atopic dermatitis,” said Lisa Swanson, MD, FAAD, while highlighting her recent Dermatology Times Case-Based Roundtable custom event titled, Navigating Atopic Dermatitis Treatment: Case-Based Discussions on Optimizing Management.
-
3 weeks ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“JAK inhibitors have really given us additional options for therapy in the last few years that we didn't have for our patients, particularly oral therapeutics, something that's been lacking in this disease space,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
4 weeks ago | 
dermatologytimes.com | Kaitlyn Bader
The 2025 American Academy of Dermatology (AAD) Annual Meeting brought together dermatology clinicians from around the globe in Orlando, Florida, for 5 days of clinical updates and networking. From March 7 to 11, this year’s AAD meeting featured more than 330 sessions with countless topics and therapeutic focuses. Dermatology Times was in Orlando conducting interviews with presenters to discuss the key data and take-home points they shared.
-
4 weeks ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“RAD is one-stop shop for everything happening in education, clinical practice, and research for atopic dermatitis,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
4 weeks ago | 
dermatologytimes.com | Kaitlyn Bader
“Dr Kwatra has built an impressive career. He has contributed invaluably to our understanding of complex dermatology conditions. His leadership in his field inspires his colleagues and is a beacon of hope for the families he serves,” said William F. Regine, MD, in an investiture ceremony honoring Shawn Kwatra, MD, as the newly endowed Dr. Joseph Warren Burnett Professor of Dermatology at the University of Maryland School of Medicine.
-
4 weeks ago | 
dermatologytimes.com | Kaitlyn Bader |Maddi Hebebrand
“We need new options. We need nonsteroidal options. We need to simplify the treatment regimen.... I think this is good news, not only for our young pediatric population but also our entire atopic dermatitis population,” Linda Stein Gold, MD, FAAD, said in an interview with Dermatology Times onsite at the 2025 American Academy of Dermatology Annual Meeting.
-
1 month ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“Chronic hand eczema can be a tricky diagnosis and a tricky thing to treat, in part because we don't always agree on what the diagnosis is. As long as you've had multiple bouts of eczema on your hands in one year, or a particular symptom of patterns that have been going on for at least 3 months, you really fit the bill for chronic hand eczema,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
1 month ago | 
dermatologytimes.com | Kaitlyn Bader
Recent research by Abraham et al evaluated the response to treatment with dupilumab in patients with hand and facial eczema with simultaneous moderate to severe atopic dermatitis (AD).1 In the poster from the 2025 American Academy of Dermatology Annual Meeting, researchers reviewed data from the TREATgermany prospective multicenter registry for adult patients with moderate to severe AD.
